Acorda Therapeutics General and Administrative Expenses 2011-2026 | ACOR

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Acorda Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
89.7 M	106 M	124 M	153 M	193 M	172 M	182 M	235 M	206 M	202 M	186 M	169 M	149 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
235 M	89.7 M	167 M

Quarterly General and Administrative Expenses Acorda Therapeutics

2024-Q1	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
28.4 M	22.5 M	-	23 M	30.1 M	26.9 M	-	29.6 M	32.4 M	34 M	-	39.9 M	38.7 M	41.1 M	-	48.7 M	50.2 M	52.7 M	-	43.6 M	44.3 M	47.6 M	-	40.7 M	49.3 M	52 M	-	54.8 M	62.6 M	59 M	-	51.1 M	52.8 M	48.8 M	-	47.8 M	50.6 M	46.9 M	-	42.3 M	48 M	48.2 M	-	40.1 M	44.2 M	38.7 M	-	34.7 M	40.1 M	37.9 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
62.6 M	22.5 M	42.8 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Celldex Therapeutics CLDX	43.8 M	$ 34.86	2.95 %	$ 2.32 B	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 4.3	8.31 %	$ 10.3 B	Australia
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Citius Pharmaceuticals CTXR	18.2 M	$ 0.87	2.3 %	$ 5.85 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Akari Therapeutics, Plc AKTX	9.28 M	$ 5.51	7.65 %	$ 371 B	Britain
Aligos Therapeutics ALGS	20.7 M	$ 6.71	-12.4 %	$ 66.3 M	USA
Alnylam Pharmaceuticals ALNY	1.21 B	$ 306.52	-4.25 %	$ 40.2 B	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Forte Biosciences FBRX	12.4 M	$ 32.69	3.99 %	$ 423 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Galectin Therapeutics GALT	5.8 M	$ 2.43	7.52 %	$ 155 M	USA
Amphastar Pharmaceuticals AMPH	85.9 M	$ 22.73	4.22 %	$ 1.06 B	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Galapagos NV GLPG	141 M	$ 29.24	1.3 %	$ 2.69 B	Belgium
Grifols, S.A. GRFS	1.06 B	$ 8.7	1.16 %	$ 6.83 B	Spain
GT Biopharma GTBP	8.95 M	$ 0.38	-4.21 %	$ 2.1 M	USA
BioNTech SE BNTX	286 M	$ 104.28	2.11 %	$ 27.2 B	Germany
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Hoth Therapeutics HOTH	6.41 M	$ 0.72	-2.61 %	$ 9.94 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 3.04	-1.17 %	$ 5 M	Israel
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
BioXcel Therapeutics BTAI	20.5 M	$ 1.17	8.88 %	$ 14.3 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
InflaRx N.V. IFRX	12 M	$ 1.55	28.75 %	$ 152 M	Germany
Akebia Therapeutics AKBA	107 M	$ 1.43	5.56 %	$ 368 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Immutep Limited IMMP	6.28 M	$ 0.6	4.21 %	$ 1.08 B	Australia
Aquestive Therapeutics AQST	79.8 M	$ 4.34	1.76 %	$ 464 M	USA
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Arcutis Biotherapeutics ARQT	275 M	$ 24.54	1.45 %	$ 3.12 B	USA
Burford Capital Limited BUR	99.3 M	$ 4.91	5.14 %	$ 792 M	Britain
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Cabaletta Bio CABA	29.6 M	$ 3.32	-5.68 %	$ 334 M	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.65	2.17 %	$ 439 M	Britain